

Recalculation of warrants of series TO 2 following rights issue

In accordance with the terms and conditions for warrants of series TO 2, which were issued in connection with the capital raise announced in April 2024, the number of shares that each warrant entitles the holder to subscribe for and the subscription price shall be recalculated following rights issues. Accordingly, SciBase Holding AB (the "Company" or "SciBase") has carried out a recalculation of warrants of series TO 2 due to the rights issue of shares that the board of directors resolved upon on September 3, 2026 (the "Rights Issue").

Following the completed recalculation, SciBase can announce that the number of shares that each warrant of series TO 2 entitles to subscribe for and the subscription price per share has changed in accordance with the following. Following the recalculation, one (1) warrant of series TO 2 entitles the holder to subscribe for 0.01 shares at a subscription price of SEK 37.47 per share.

Following the recalculation, one (1) warrant of series TO 2 entitles the holder to subscribe for 0.01 new shares in the Company during the period from and including on 3 April 2029, until and including 17 April 2029.

The terms and conditions for the warrants, including potential adjustments due to future share issues, are available on the Company's website.

For additional information, please contact:

Michael Colérus, CEO, tel. +46703413472, e-mail: pia.renaudin@scibase.com

The information was submitted for publication, through the agency of the contact person set out above, on October 7, 2026 at 08.00 CET.

Certified Advisor (CA):

DNB Carnegie Investment Bank AB [publ] Phone: +46 8 588 68 570, E-mail: certifiedadviser@carnegie.se

About SciBase:

SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops, manufactures, and commercializes Nevisense, a unique point-of-care platform that combines AI and advanced EIS technology to elevate diagnostic accuracy, ensuring proactive skin health management.

Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.

Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.

The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015 and the company's Certified Adviser is DNB Carnegie Investment Bank AB [publ]. Learn more at www.scibase.com. For press releases and financial reports visit: <http://investors.scibase.se/en/pressreleases>